A PROJECT REPORT FOR

THE DEGREE OF BACHELOR IN MEDICAL

LABORATORY TECHNOLOGY
SESSION : 2020-2024

TUBERCULOSIS : A COMPREHENSIVE
STUDY

MAHAVIR PARAMEDICAL TRAINING

AND
RESEARCH INSTITUTE , PATNA

SUBMITTED BY : SIDDHARTHA SUDERSHAN UNDER THE

GUIDANCE OF :
REG. NO. : 20307335020 MISS.
NIDHI KUMARI
ROLL NO : 57 M.Sc.
(Microbiology)
COURSE : BMLT H.O.D.
DEPARTMENT OF
PATHOLOGY

DEPARTMENT OF MEDICAL LAB

TECHNOLOGY
MAHAVIR PARAMEDICAL AND TRAINING INSTITUTE

CERTIFICATE
This is to certify that the Project work entitled TUBERCULOSIS: A
COMPREHENSIVE STUDY has been carried out by the candidate
SIDDHARTHA SUDERSHAN himself/herself under our direct supervision
and guidance. The techniques and methods described were undertaken by the
candidate himself/herself and observations have been periodically checked by
us.

GUIDE:
MISS NIDHI
H.O.D.
PATHOLOGY
 ACKNOWLEDGEMENT

“Gratitude is the best medicine. It heals your mind, your body and your spirit.
And attracts more things to be grateful for”

At the very outset, I would like to express my utmost gratitude to my chief guide and
supervisor MISS NIDHI (Professor and Head of the Department), Department of
Pathology for her sincere and selfless support, prompt and useful advice. She gives
me a lifetime unforgettable memory of his guidance, patience, intelligence, diligence
and erudition.
I feel short of words to express my love and gratitude for my loving parents whose
unending love, countless sacrifices, constant unconditional support and reassurances
have given me the courage to face all the ups and downs in my life. I am forever
indebted to them and all that I am today, I owe it to them

BY :
SIDDHARTHA SUDERSHAN
REG. NO. :
20307335020
ROLL NO : 57
 COURSE : BMLT

DECLARATION

I Hereby Declare That This Project Work On “Tuberculosis : A

Comprehensive Study” Is My Own Work And Had Been Written
And Completed By Me And I Am Thankful To My Teachers And My
Seniors Who Helped A Lot In Completion Of This Project Work.

BY :
SIDDHARTHA SUDERSHAN
REG. NO. :
20307335020
ROLL NO : 57
COURSE : BMLT
 CONTENTS

1. Introduction
o History and Background
o Global Impact
o Objectives of the Study

2. Epidemiology of Tuberculosis
o Prevalence and Incidence Rates
o High-Risk Regions and Populations

3. Pathophysiology
o Causative Agent (Mycobacterium tuberculosis)
o Transmission Modes
o Disease Progression
4. Clinical Manifestations
o Symptoms of Pulmonary and Extrapulmonary TB
o Diagnostic Criteria

5. Diagnosis
o Traditional Methods (Microscopy, Culture)
o Modern Techniques (PCR, GeneXpert)
o Challenges in Diagnosis

6. Treatment Protocols
o First-Line and Second-Line Drugs
o Drug-Resistant TB
o Treatment Monitoring

7. Public Health Perspective

o WHO Initiatives and Programs
o National TB Control Programs
o Vaccination: BCG and Beyond
8. TB in Special Populations
o Children
o HIV Co-Infected Individuals
o Pregnant Women

9. Challenges in TB Eradication
o Socioeconomic Barriers
o Stigma and Awareness
o Drug Resistance

10. Research and Innovations

o Vaccine Development
o New Therapeutic Approaches
o Technological Advances in Diagnosis

11. Case Studies

o Successful TB Eradication Programs
o Community-Based Interventions
12. Discussion and Recommendations
o Policy Suggestions
o Integrating TB Care with General Healthcare

13. Conclusion
o Summary of Findings
o Future Directions

14. References
o Books, Journals, Websites

15. Appendices
 1. Introduction

1.1 History of Tuberculosis

Tuberculosis (TB) has been a global concern for centuries. It has been
described in ancient texts and medical manuscripts. Evidence of TB can
be traced back to ancient Egyptian mummies, where skeletal remains
show signs of the disease. In 1882, Robert Koch discovered
Mycobacterium tuberculosis, which led to a breakthrough in
understanding the bacteriology of TB and its transmission. The disease
was called “consumption” due to its characteristic weight loss and
wasting. Although TB has been recognized for centuries, it continues to
cause significant morbidity and mortality worldwide.
1.2 Modern Context of TB
Tuberculosis is still one of the most prevalent infectious diseases
globally, with more than 10 million people affected annually, primarily
in developing countries. The World Health Organization (WHO) has
declared it a global health emergency. Despite the availability of
effective treatment, TB remains a leading cause of death among
infectious diseases, mainly due to multidrug-resistant (MDR) strains and
poor healthcare infrastructure in many parts of the world.

1.3 Objectives of the Study

This study aims to:
Investigate the epidemiology of TB.
Explore clinical features and diagnosis.
  Review treatment protocols and challenges in TB control.
 Assess the socio-economic impact of TB globally.
 Highlight recent innovations in research and drug development.

The study of tuberculosis (TB) addresses a wide range of goals,

encompassing its prevention, diagnosis, treatment, and broader societal
impact. This detailed document outlines the key objectives of TB
research and intervention efforts, expanded to provide a comprehensive
understanding.

1. Understanding Disease Epidemiology

a. Global and Regional Trends
 Conduct in-depth analysis of global TB incidence, prevalence, and
mortality rates.
 Examine regional variations and identify high-burden areas for targeted
interventions.
b. Demographic and Socioeconomic Factors
 Study the impact of age, gender, and socioeconomic status on TB
occurrence.
 Assess how migration, urbanization, and poverty influence TB spread
and management.

c. Impact of Co-Morbidities
 Investigate the relationship between TB and conditions such as
HIV/AIDS, diabetes, and malnutrition.
 Explore how co-infections and chronic illnesses exacerbate TB
progression and outcomes.

2. Advancing Diagnostic Techniques

a. Development of Rapid Diagnostic Tools
 Innovate diagnostic technologies to provide quicker and more accurate
detection of active TB and latent TB infections (LTBI).
 Improve methods for identifying drug-resistant strains, such as
multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB
(XDR-TB).
b. Biomarker Discovery
 Identify and validate biomarkers that differentiate LTBI from active
TB.
 Develop tools for early detection of TB reactivation risks.

c. Improving Accessibility
 Ensure diagnostic tools are affordable and accessible in low-resource
settings.
 Strengthen laboratory infrastructure and training programs in high-
burden countries.

3. Studying Pathogenesis and Immunology

a. Host-Pathogen Interaction
 Investigate the mechanisms by which Mycobacterium tuberculosis
evades the immune system.
 Study granuloma formation and its role in containing or promoting TB
infection.

b. Immune Response Dynamics

 Explore the innate and adaptive immune responses to TB.
 Examine factors influencing susceptibility and resistance to TB,
including genetic predispositions.

c. Mechanisms of Latency and Reactivation

 Analyze how M. tuberculosis enters and maintains a dormant state.
 Identify triggers that lead to reactivation of latent TB.

4. Enhancing Treatment Strategies

a. Development of New Drugs
 Research novel anti-TB drugs targeting different stages of the bacterial
life cycle.
 Shorten treatment durations and reduce side effects to improve patient
compliance.

b. Optimizing Existing Regimens

 Evaluate the efficacy of current treatment regimens for both drug-
susceptible and drug-resistant TB.
 Address drug interactions, especially in TB-HIV co-infected
individuals.

c. Treatment Adherence Strategies

 Develop strategies to improve treatment adherence, such as directly
observed therapy (DOT).
 Study the psychological and social factors influencing patient
adherence.

5. Preventing TB Transmission
a. Vaccination Strategies
 Assess the efficacy of the Bacille Calmette-Guérin (BCG) vaccine in
different populations.
 Develop next-generation vaccines with higher efficacy and broader
coverage.

b. Public Health Interventions

 Evaluate the impact of infection control measures, such as ventilation
improvements and mask use, in healthcare and community settings.
 Promote active case finding and contact tracing to prevent
transmission.
c. Community Engagement
 Educate communities about TB symptoms and preventive measures.
 Address cultural and societal barriers to TB prevention and treatment.

6. Addressing Drug Resistance

a. Mechanisms of Resistance
 Study the genetic mutations and environmental factors contributing to
MDR-TB and XDR-TB.
 Explore the role of improper drug use and treatment non-compliance in
resistance development.

b. Diagnostic and Therapeutic Advances

 Develop rapid diagnostic methods to detect drug-resistant strains.
 Investigate novel therapies and combination treatments for resistant
TB.
c. Prevention Strategies
 Strengthen drug-supply chains to prevent stockouts and ensure proper
medication use.
 Train healthcare workers in managing drug-resistant TB cases
effectively.

7. Improving Public Health Policies

a. Program Evaluation
Assess the effectiveness of national and international TB control
programs.
Identify gaps in implementation and propose solutions to enhance
impact.
b. Resource Allocation
 Advocate for increased funding and resources for TB research and
healthcare delivery.
 Ensure equitable distribution of resources to high-burden and
underserved populations.
c. Policy Recommendations
 Develop evidence-based policies to support TB elimination goals.
  Promote integration of TB control efforts with other public health
initiatives.

8. Strengthening Healthcare Systems

a. Capacity Building
Train healthcare professionals in TB diagnosis, treatment, and
prevention.
Expand healthcare infrastructure to reach remote and underserved
areas.
b. Integration of Services
 Integrate TB services with HIV care, maternal and child health
programs, and non-communicable disease management.
 Streamline healthcare delivery to improve patient outcomes.
c. Use of Technology
 Leverage digital health tools for TB surveillance, treatment monitoring,
and patient education.
  Implement electronic medical records to track patient progress and
outcomes.

9. Community and Social Objectives

a. Raising Awareness
Conduct campaigns to educate the public about TB symptoms,
transmission, and treatment.
Address stigma and discrimination associated with TB.
b. Empowering Vulnerable Groups
 Focus on marginalized populations, including refugees, prisoners, and
individuals in poverty.
 Ensure access to TB care for all, irrespective of socioeconomic status.
c. Social Research
 Study the social determinants of health that contribute to TB
vulnerability.
 Develop interventions to address these determinants effectively.
10. Research and Innovation
a. Basic Research
Investigate the molecular biology of Mycobacterium tuberculosis and
host-pathogen interactions.
Study the evolution and adaptability of the bacterium in different
environments.
b. Clinical Trials
 Conduct trials to evaluate new drugs, vaccines, and diagnostic tools.
 Involve diverse populations to ensure generalizability of results.
c. Operational Research
 Examine the implementation and scalability of TB control
interventions.
 Identify best practices and lessons learned from successful programs.
 2. Epidemiology of Tuberculosis

Epidemiology of Tuberculosis (TB)

Tuberculosis (TB) remains one of the leading infectious diseases
globally, posing significant public health challenges. Understanding its
epidemiology involves analyzing its distribution, determinants, and
control measures across different populations and regions. Below is an
in-depth exploration of the epidemiology of TB.
 1. Global Burden of TB

a. Incidence and Prevalence

 Incidence: According to the World Health Organization (WHO),
approximately 10 million people develop TB annually.
 Prevalence: The global prevalence of TB has been declining steadily
due to improved control measures.

b. Mortality
 TB is one of the top 10 causes of death worldwide.
 In 2021, TB caused approximately 1.6 million deaths, including those
among people living with HIV.
c. High-Burden Countries
 The WHO identifies 30 high TB burden countries that account for
about 87% of the world's TB cases.
 India, China, and Indonesia are among the top contributors to global
TB cases.

2. Geographical Distribution
a. Regions with High TB Burden
Asia and Africa: These regions account for the majority of global TB
cases due to factors like high population density, poverty, and limited
healthcare access.
Sub-Saharan Africa: Has the highest TB incidence per capita, largely
due to the high prevalence of HIV.
b. Low-Burden Regions
 Developed regions like North America and Western Europe have low
TB incidence rates, mainly due to effective healthcare systems and
preventive measures.

c. Urban vs. Rural Distribution

 Urban areas often have higher TB rates due to overcrowding, poor
ventilation, and increased exposure to infected individuals.
3. Risk Factors for TB
a. Biological Factors
 HIV Co-Infection: HIV weakens the immune system, making
individuals more susceptible to TB.
 Diabetes: Increases the risk of developing TB threefold.
 Malnutrition: Weakens the immune response, facilitating TB
infection.
b. Social Determinants
 Poverty: Poor living conditions, malnutrition, and lack of healthcare
access increase TB risk.
 Overcrowding: Promotes the spread of TB through airborne
transmission.
 Migration: Migrants from high-burden areas are at greater risk of TB.

c. Behavioral Factors
 Smoking and alcohol abuse are associated with an increased risk of
TB.
 Poor adherence to treatment regimens leads to drug-resistant TB.

4. Demographic Patterns
a. Age
 TB affects all age groups, but the highest burden is among adults aged
15-44.
 Children under 5 years are at high risk of severe forms of TB.

b. Gender
 Men are more likely to develop active TB than women, possibly due to
behavioral and occupational exposure.
 Women, however, face significant stigma and barriers to healthcare
access in many settings.

c. Vulnerable Populations
 People in prisons, refugee camps, and slums are at increased risk of
TB.
 Healthcare workers are also at risk due to frequent exposure to TB
patients.

5. TB and HIV Co-Infection

a. Dual Epidemic
 HIV significantly increases the risk of TB infection and progression to
active disease.
 Approximately 8% of TB cases globally are co-infected with HIV.

b. Geographical Overlap
 Sub-Saharan Africa is the epicenter of the TB-HIV co-epidemic.

c. Impact on Mortality
 TB is the leading cause of death among people living with HIV.

6. Drug-Resistant TB (DR-TB)
a. Types of Drug Resistance
 Multidrug-Resistant TB (MDR-TB): Resistant to isoniazid and
rifampicin.
 Extensively Drug-Resistant TB (XDR-TB): Resistant to first-line and
several second-line drugs.

b. Global Burden
 In 2021, there were approximately 500,000 cases of MDR-TB.
 Drug-resistant TB is a growing public health concern due to its high
treatment cost and lower success rates.

c. Risk Factors
 Incomplete or improper treatment.
 Transmission of resistant strains.
 Limited access to quality healthcare.

7. Impact of Social and Economic Factors

a. Poverty and Inequality
 Poverty exacerbates TB risk through malnutrition, poor housing, and
limited access to healthcare.

b. Healthcare Access
 Delayed diagnosis and treatment contribute to the spread of TB.
 Many low-income countries face challenges in providing TB
diagnostics and medications.

c. Stigma and Discrimination

 Fear of social ostracism prevents individuals from seeking timely
diagnosis and treatment.

8. TB Control and Prevention

a. BCG Vaccination
 The Bacillus Calmette-Guérin (BCG) vaccine provides partial
protection against severe forms of TB in children.

b. Preventive Therapy
 Isoniazid preventive therapy (IPT) is recommended for individuals at
high risk, such as those with latent TB infection and HIV.

c. Public Health Strategies

 Case detection through active surveillance.
 Ensuring adherence to treatment regimens through directly observed
therapy (DOT).
 Addressing social determinants like poverty and overcrowding.

d. Global Initiatives
 The WHO’s End TB Strategy aims to reduce TB deaths by 90% and
incidence by 80% by 2030.

Conclusion
The epidemiology of TB highlights the significant global burden of this
disease and the complex interplay of biological, social, and economic
factors contributing to its spread. Efforts to combat TB must focus on
addressing these determinants, improving healthcare access, and
enhancing public health interventions. Achieving global TB control
requires a concerted effort from governments, healthcare providers, and
communities.

2.1 Global Prevalence

Globally, tuberculosis remains one of the top 10 causes of death.

Countries in Southeast Asia, Sub-Saharan Africa, and Eastern Europe
have the highest burden of TB. In 2022, there were an estimated 10.6
million new TB cases worldwide, with 1.6 million deaths.

 Top 5 TB-Burden Countries:

India (2.5 million cases annually)
o

China
o

Indonesia
o

Philippines
o

Pakistan
o
2.2 Vulnerable Populations

Certain populations are more susceptible to TB, including:

 HIV/TB Co-Infection: HIV weakens the immune system, making

individuals more vulnerable to developing TB.


 Children: Pediatric TB is often underdiagnosed, with symptoms that

may be mistaken for other diseases.


 Prisoners: High-density living conditions and poor healthcare lead to

high TB transmission rates in prisons.


 Malnourished and Immune-Compromised Individuals: These

groups have a weakened ability to fight infections, increasing TB
susceptibility.
2.3 Key Statistics and Trends
In 2020, TB cases decreased slightly due to the COVID-19 pandemic
disrupting TB services globally. However, the impact of delayed
diagnosis and treatment led to a rise in TB-related deaths.

 Incidence: TB incidence has been declining at 2% per year, but this

progress is slow.


 Mortality Rate: TB-related deaths, especially in patients with MDR-

TB and HIV, remain high.

 3. Pathophysiology of Tuberculosis
Pathophysiology of Tuberculosis (TB)
Tuberculosis (TB) is a complex infectious disease caused by the
bacterium Mycobacterium tuberculosis. It primarily affects the lungs but
can disseminate to other parts of the body. The pathophysiology of TB
involves intricate interactions between the pathogen and the host's
immune system. This document provides an in-depth exploration of the
mechanisms underlying TB.

1. Pathogen Characteristics
a. Structure and Virulence of M. tuberculosis
 Cell Wall Composition: The bacterium’s lipid-rich cell wall,
including mycolic acids, confers resistance to desiccation, antibiotics,
and host immune responses.
 Virulence Factors:
oCord Factor: A glycolipid that inhibits immune responses and
contributes to granuloma formation.
oESX-1 Secretion System: Facilitates evasion of host defenses by
secreting proteins that disrupt phagolysosome formation.
oDormancy Genes: Enable the bacterium to enter a latent state under
hostile conditions.
b. Growth and Survival
 M. tuberculosis is a slow-growing obligate aerobe, thriving in oxygen-
rich environments like the lungs.
 The bacterium survives intracellularly within macrophages, evading
host immune mechanisms.

2. Transmission and Initial Infection

a. Inhalation
TB is primarily transmitted via respiratory droplets from individuals
with active pulmonary TB.
Droplets containing M. tuberculosis are inhaled and deposited in the
alveoli of the lungs.
b. Primary Infection
 Alveolar macrophages engulf the bacteria through phagocytosis.
 M. tuberculosis inhibits phagosome-lysosome fusion, allowing it to
survive and replicate within macrophages.

4. Innate Immune Response

a. Early Host Defense
 Toll-like receptors (TLRs) on macrophages recognize bacterial
components, triggering the release of pro-inflammatory cytokines like
tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β).
 Neutrophils and monocytes are recruited to the site of infection.


b. Granuloma Formation
 Granulomas are organized immune structures formed to contain the
infection. They consist of:
oA core of infected macrophages and necrotic tissue.
oA surrounding layer of lymphocytes (CD4+ and CD8+ T cells) and
other immune cells.
 Granulomas aim to prevent bacterial spread but also provide a niche
for bacterial persistence.

5. Adaptive Immune Response

a. T Cell Activation
 Dendritic cells present M. tuberculosis antigens to naive T cells in
lymph nodes, activating CD4+ and CD8+ T cells.
  CD4+ T cells secrete interferon-gamma (IFN-γ), which enhances
macrophage bactericidal activity.


b. Role of CD8+ T Cells

 CD8+ T cells kill infected cells via cytotoxic mechanisms and secrete
cytokines that aid macrophage activation.


c. Antibody Response
 While B cells produce antibodies against M. tuberculosis, the role of
humoral immunity in controlling TB is limited compared to cell-
mediated immunity.

5. Latent TB Infection (LTBI)

a. Bacterial Persistence
 In most cases, the immune system contains the bacteria within
granulomas, leading to latent infection.
 Latent M. tuberculosis remains viable but non-replicative, capable of
reactivation under favorable conditions.
b. Immune Surveillance
 Continuous immune activity, particularly by CD4+ T cells and
macrophages, is required to maintain latency.

6. Progression to Active TB
a. Reactivation Triggers
 Reactivation occurs when the immune system is compromised, such as
in:
oHIV infection
oMalnutrition
oDiabetes
oImmunosuppressive therapies (e.g., corticosteroids, chemotherapy)
o

b. Pathological Changes
 Breakdown of granulomas leads to bacterial release and uncontrolled
replication.
 Tissue necrosis, caseation, and cavitation occur, resulting in lung
damage and symptom manifestation (e.g., cough, fever, weight loss).

7. Dissemination of TB
a. Hematogenous Spread
 Bacteria can spread through the bloodstream to extrapulmonary sites
such as:
oLymph nodes
oBones (Pott’s disease)
oCentral nervous system (CNS) leading to tuberculous meningitis
oKidneys

b. Miliary TB
 Disseminated TB occurs when bacteria spread widely via the
bloodstream, forming tiny lesions in multiple organs.

8. Immune Evasion Strategies of M. tuberculosis

a. Inhibition of Phagosome-Lysosome Fusion
Prevents bacterial degradation within macrophages.
b. Suppression of Antigen Presentation
 Reduces activation of T cells by downregulating MHC class II
expression on infected macrophages.
c. Resistance to Reactive Species
Neutralizes reactive oxygen and nitrogen species produced by
macrophages.
d. Manipulation of Host Metabolism
 Alters macrophage lipid metabolism to create a nutrient-rich
environment for bacterial survival.

9. Host-Pathogen Interaction Outcomes

a. Successful Containment
Granulomas effectively wall off bacteria, preventing disease
progression.
b. Active Disease
 Insufficient immune response leads to bacterial proliferation and tissue
damage.
c. Chronic Inflammation
 Prolonged immune activation can result in fibrosis, scarring, and
permanent lung damage.

10. Pathophysiological Manifestations

a. Pulmonary TB
Chronic cough with sputum production, hemoptysis, chest pain, and
progressive respiratory failure.
b. Extrapulmonary TB
 Symptoms depend on the affected organ, such as lymphadenopathy,
bone pain, or neurological deficits.
c. Systemic Symptoms
 Fever, night sweats, weight loss, and fatigue

5.1 Causative Agent

The causative agent of tuberculosis is Mycobacterium tuberculosis, a

slow-growing, acid-fast bacillus. It primarily infects the lungs, but it can
spread to other organs such as the kidneys, bones, and brain, causing
extrapulmonary TB. The bacterium has a unique lipid-rich cell wall that
makes it resistant to many conventional antibiotics.
3.2 Mechanism of Infection
Mechanism of Infection of Tuberculosis (TB)
Tuberculosis (TB) is a highly infectious disease caused by the bacterium
Mycobacterium tuberculosis. It primarily affects the lungs but can spread
to other parts of the body. Understanding the mechanism of TB infection
involves studying its transmission, host-pathogen interactions, and
immune responses. Below is a detailed exploration of the mechanism of
TB infection.

1. Transmission of TB
a. Airborne Spread
TB is transmitted through the inhalation of airborne droplets expelled
when an infected person coughs, sneezes, or speaks. These droplets
contain M. tuberculosis bacteria and can remain suspended in the air for
hours.
b. Risk Factors for Transmission
 Prolonged exposure to an infected individual.
 Overcrowded and poorly ventilated environments.
 Weakened immune systems (e.g., due to HIV, malnutrition, or other
illnesses).
2. Pathogen Characteristics
a. Structure of M. tuberculosis
The bacterium has a lipid-rich cell wall, primarily composed of
mycolic acids, which confer resistance to desiccation and many
antibiotics.
It is an acid-fast bacillus, detectable using special staining techniques
like Ziehl-Neelsen staining.
b. Virulence Factors
 Cord Factor: Helps inhibit immune response and promotes granuloma
formation.
 ESX-1 Secretion System: Facilitates the release of bacterial proteins
that modulate host immunity.
 Lipids and Glycolipids: Aid in evading immune detection and
facilitating survival within host cells.
3. Initial Infection and Colonization
a. Inhalation and Deposition
 After inhalation, M. tuberculosis bacteria travel through the respiratory
tract and settle in the alveoli of the lungs.
 The bacteria are phagocytosed by alveolar macrophages, the first line
of immune defense in the lungs.

b. Survival Inside Macrophages

 M. tuberculosis can survive and replicate within macrophages by
inhibiting phagosome-lysosome fusion.
 The bacterium secretes proteins that neutralize reactive oxygen and
nitrogen species produced by the macrophages.
4. Immune Response to Infection
a. Innate Immune Response
 Activation of toll-like receptors (TLRs) on macrophages and dendritic
cells leads to the release of cytokines, such as tumor necrosis factor-
alpha (TNF-α) and interleukin-12 (IL-12).
 These cytokines recruit additional immune cells, including neutrophils
and monocytes, to the site of infection.

b. Granuloma Formation
 The immune system forms granulomas around the infected
macrophages to contain the bacteria.
 Granulomas consist of a central core of infected macrophages and a
surrounding layer of T cells, B cells, and other immune cells.

c. Adaptive Immune Response

 CD4+ T cells play a critical role by producing interferon-gamma (IFN-
γ), which activates macrophages to kill the bacteria.
 CD8+ T cells contribute by lysing infected cells and releasing
additional cytokines.
5. Latent TB Infection
In most cases, the immune system successfully contains the bacteria
within granulomas, leading to a latent TB infection (LTBI).
Latent bacteria can persist for years without causing symptoms but
remain viable and capable of reactivation.

6. Progression to Active TB Disease

a. Factors Leading to Reactivation
 Weakening of the immune system (e.g., due to HIV, diabetes, or
aging).
 Malnutrition and stress.
 Immunosuppressive therapies, such as corticosteroids or
chemotherapy.

b. Pathological Changes
 Reactivation results in the breakdown of granulomas and the release of
bacteria into surrounding tissues.
 Necrosis and cavitation occur in lung tissue, leading to the production
of sputum laden with bacteria.

7. Dissemination of TB
  In some cases, TB spreads beyond the lungs to other organs, leading to
extrapulmonary TB.
 Common sites of dissemination include the lymph nodes, bones,
central nervous system (CNS), and kidneys.
 This occurs via lymphatic or hematogenous routes.

8. Immune Evasion Mechanisms

M. tuberculosis downregulates antigen presentation, impairing the
activation of T cells.
The bacterium alters macrophage metabolism to promote survival.
It secretes proteins that suppress the production of pro-inflammatory
cytokines.


9. Host-Pathogen Interaction Outcomes

a. Successful Containment
 The immune system contains the infection within granulomas,
preventing disease progression.
b. Active TB Disease
 Occurs when the immune response is insufficient to control bacterial
replication.
c. Chronic Infection
 Persistent immune activation can lead to tissue damage and scarring.

Conclusion
The mechanism of TB infection highlights the complex interplay
between M. tuberculosis and the host immune system. While the immune
system often contains the infection, the bacterium's ability to survive
within host cells and evade immune defenses poses significant
challenges. Understanding these mechanisms is essential for developing
effective treatments and preventive strategies.
The transmission of TB occurs primarily through inhalation of droplets
from an infected person's cough or sneeze. Once inhaled, the bacteria
reach the alveoli of the lungs, where they are engulfed by macrophages.
In most cases, the immune system controls the infection, leading to latent
TB. However, if the immune system is compromised, the bacteria
multiply, causing active TB.

1. Latent Tuberculosis: In most cases, the bacteria remain dormant in

the lungs, and the individual does not show symptoms or become
contagious.

2. Active Tuberculosis: If the immune system fails to control the

infection, it becomes active, leading to symptoms such as coughing,
fever, and weight loss. Active TB is contagious and can spread to
others.
3.3 Extrapulmonary Tuberculosis
Extrapulmonary TB occurs when the infection spreads beyond the lungs
to other organs. This includes TB meningitis (affecting the brain), TB of
the spine (Pott’s disease), and TB of the bones and joints.
Extrapulmonary TB is more common in immunocompromised
individuals, such as those with HIV.

3. Clinical Manifestations of Tuberculosis

4.1 Pulmonary Tuberculosis

Pulmonary TB is the most common form of the disease, with symptoms
including:
Persistent cough for more than 3 weeks.
Hemoptysis (coughing up blood).
Chest pain.
Shortness of breath.
Fever, night sweats, and weight loss (classic symptoms).

4.2 Extrapulmonary Tuberculosis

Extrapulmonary TB can manifest in various forms, such as:
Extrapulmonary tuberculosis (EPTB) refers to tuberculosis (TB)
infections occurring outside the lungs. While pulmonary TB is the most
common form, EPTB accounts for a significant proportion of TB cases,
particularly in immunocompromised individuals. This document provides
a comprehensive overview of EPTB, its manifestations, diagnosis,
treatment, and public health implications.

1. Definition and Epidemiology

a. Definition
 EPTB occurs when Mycobacterium tuberculosis infects organs other
than the lungs, such as lymph nodes, pleura, bones, central nervous
system, genitourinary tract, and abdomen.
b. Epidemiological Trends
 EPTB constitutes approximately 15-20% of TB cases in
immunocompetent individuals and up to 50% in HIV-positive patients.
 Risk factors include HIV/AIDS, diabetes, malnutrition, and
immunosuppressive therapies.
c. Global Burden
 Regions with high TB prevalence, such as sub-Saharan Africa and
South Asia, report a higher incidence of EPTB.
 Improved surveillance systems have led to better recognition of EPTB
cases in low-prevalence countries.

2. Pathophysiology
a. Dissemination of TB Bacilli
 TB bacilli spread hematogenously or via lymphatics from the primary
infection site.
 The bacilli may localize in extrapulmonary sites due to immune or
anatomical factors.
b. Role of Host Immunity
 Immunodeficiency, such as in HIV, facilitates the dissemination and
establishment of EPTB.
 The formation of granulomas in extrapulmonary sites reflects the host
immune attempt to contain the infection.

3. Clinical Manifestations
a. Lymph Node TB (Tuberculous Lymphadenitis)
Most common form of EPTB.
Symptoms include painless swelling of lymph nodes, typically
cervical.
b. Pleural TB
 Involves infection of the pleura, leading to pleural effusion.
 Symptoms include chest pain, dyspnea, and fever.
c. Skeletal TB (Pott's Disease)
Affects bones and joints, particularly the spine.
Symptoms include back pain, deformity, and neurological deficits.
d. CNS TB
 Includes tuberculous meningitis and tuberculomas.
 Symptoms: headache, fever, altered mental status, and neurological
deficits.
e. Abdominal TB
 Affects the peritoneum, intestines, or abdominal lymph nodes.
 Symptoms: abdominal pain, ascites, and weight loss.
f. Genitourinary TB
Involves kidneys, bladder, or genital organs.
Symptoms: dysuria, hematuria, infertility.
g. Other Forms
 Cardiac TB: rare but involves the pericardium.
 Cutaneous TB: presents as ulcers or nodules on the skin.

4. Diagnosis
a. Clinical Evaluation
 Detailed history and physical examination focusing on TB risk factors
and symptoms.
b. Laboratory Tests
 Microscopy and Culture: Gold standard but time-consuming.
 Molecular Tests: Xpert MTB/RIF for rapid detection and drug
resistance testing.
c. Imaging
Chest X-ray and CT scan for pleural or lymph node involvement.
MRI for CNS and skeletal TB.
d. Histopathology
 Biopsy of affected tissues showing granulomas with caseation necrosis.
e. Specialized Tests
 Adenosine deaminase (ADA) levels in pleural or ascitic fluid.
 PCR for specific identification of TB DNA.

5. Treatment
a. Pharmacological Therapy
Same principles as pulmonary TB but often extended duration.
Standard regimen: 2 months of intensive phase (isoniazid, rifampicin,
pyrazinamide, ethambutol) followed by 4-7 months of continuation
phase (isoniazid, rifampicin).
CNS TB requires a minimum of 9-12 months of therapy.
b. Corticosteroids
 Used as adjunctive therapy in pleural TB, pericardial TB, and CNS TB
to reduce inflammation.
c. Surgical Interventions
 Reserved for complications such as spinal deformities, abscess
drainage, or obstruction in abdominal TB.

6. Challenges in Management
a. Diagnostic Delays
Nonspecific symptoms and limited access to diagnostic tools contribute
to delays.
b. Drug Resistance
 Multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB
(XDR-TB) complicate treatment.
c. Comorbidities
 HIV co-infection increases the complexity of diagnosis and treatment.
d. Healthcare Infrastructure
 Limited resources in low-income settings hinder effective
management.

7. Public Health Implications

a. Impact on Healthcare Systems
EPTB cases require multidisciplinary management, straining
healthcare resources.
b. Surveillance and Reporting
 Strengthened surveillance systems are essential for early detection and
reporting.
c. Community Awareness
 Educating communities about TB symptoms beyond pulmonary
manifestations can improve healthcare-seeking behavior.
8. Research and Future Directions
a. Improved Diagnostics
Development of point-of-care tests for rapid EPTB detection.
b. Novel Therapeutics
 Research on shorter treatment regimens and new drug formulations.
c. Vaccine Development
Efforts to develop vaccines that prevent both pulmonary and
extrapulmonary TB.
d. Understanding Pathogenesis
 Further study of factors driving extrapulmonary dissemination.
  TB Meningitis: A severe form of TB that affects the brain and
meninges, leading to headaches, confusion, and neurological deficits.
 Bone and Joint TB: Known as Pott’s disease, it affects the spine and
can cause deformities and neurological damage.
 Lymphadenitis: Swelling of the lymph nodes, typically seen in the
 neck.

4.3 Complications of Tuberculosis

If left untreated, TB can lead to severe complications such as lung
fibrosis, respiratory failure, or death. Individuals with active TB who are
not treated may spread the infection to others, exacerbating public health
concerns.
5. Diagnosis of Tuberculosis
5.1 Traditional Diagnostic Methods

 Sputum Smear Microscopy: A basic diagnostic method that involves

staining sputum samples with special dyes to detect acid-fast bacilli.
This test is inexpensive but lacks sensitivity, especially in HIV-infected
individuals.

 Chest X-rays: Used to visualize lung damage caused by TB, although

not definitive for diagnosing TB.

 Tuberculin Skin Test (TST): Involves injecting purified protein

derivative under the skin. If the person has been exposed to TB, they
will develop a raised bump at the injection site.
5.2 Advanced Diagnostic Methods

 GeneXpert MTB/RIF: A rapid molecular test that detects TB DNA

and rifampicin resistance in less than 2 hours. It is widely used in high-
burden countries.

 Interferon-Gamma Release Assays (IGRA): Blood tests that

measure the immune response to TB antigens and are useful for
detecting latent TB infection.
5.3 Challenges in Diagnosis

Tuberculosis (TB) remains a major public health issue worldwide,

particularly in low- and middle-income countries. Accurate and timely
diagnosis is critical to managing the disease, but numerous challenges
complicate this process. These challenges arise due to the nature of the
disease, limitations of diagnostic tools, and systemic issues in healthcare
delivery. Below is an in-depth exploration of the barriers to effective TB
diagnosis.

1. Asymptomatic and Latent Tuberculosis

One of the most significant challenges in diagnosing TB is the
asymptomatic nature of latent TB infection (LTBI). Individuals with
LTBI do not exhibit symptoms such as persistent cough, fever, or weight
loss, making early detection extremely difficult. Without active
symptoms, these cases often go undiagnosed until they progress to active
TB, which is contagious and poses a greater risk to public health.
Screening methods for latent TB, such as the Tuberculin Skin Test (TST)
or Interferon-Gamma Release Assays (IGRAs), are available but cannot
differentiate between latent and active TB, limiting their diagnostic
utility

2. Non-Specific Symptoms of Active Tuberculosis

Active TB often presents with symptoms such as prolonged cough, fever,
night sweats, weight loss, and fatigue. However, these symptoms are
non-specific and overlap with those of other respiratory and systemic
illnesses, such as pneumonia, chronic obstructive pulmonary disease
(COPD), or malignancies. This overlap can lead to misdiagnosis or
delays in initiating appropriate treatment.

3. Challenges in Sample Collection

Obtaining appropriate biological samples is critical for diagnosing TB,
but this process is fraught with challenges:
Sputum Collection: Diagnosing pulmonary TB often relies on sputum
samples. However, many patients, particularly children and individuals
with HIV or extrapulmonary TB, cannot produce sufficient sputum.
Extrapulmonary TB: In cases where TB affects organs other than the
lungs (e.g., lymph nodes, spine, abdomen), obtaining diagnostic
samples may require invasive procedures like biopsies or aspirates,
which may not be readily available in resource-limited settings.

4. Limitations of Diagnostic Tests

a. Microscopic Examination
The Ziehl-Neelsen (ZN) stain for acid-fast bacilli (AFB) is a widely used
diagnostic tool, but it has low sensitivity, especially in patients with low
bacterial loads. Smear microscopy often fails to detect TB in children,
individuals with HIV co-infection, and patients with extrapulmonary TB.
b. Culture Methods
Culture tests, such as those using Lowenstein-Jensen media, are
considered the gold standard for TB diagnosis. While highly sensitive
and specific, these tests require several weeks to produce results,
delaying treatment.
c. Molecular Diagnostics
Tests like GeneXpert MTB/RIF have revolutionized TB diagnosis by
providing rapid and accurate detection, including rifampicin resistance.
However, these tests are costly and require specialized equipment and
trained personnel, limiting their availability in low-resource settings.
d. Immunological Tests
TST and IGRA are useful for detecting TB infection but cannot
distinguish between active and latent TB. Moreover, their reliability is
compromised in individuals vaccinated with Bacillus Calmette-Guérin
(BCG) or those with immunosuppression.

5. HIV Co-Infection
TB is a leading cause of morbidity and mortality among people living
with HIV. Diagnosing TB in this population is particularly challenging
for several reasons:
Atypical presentations: HIV-positive individuals may not exhibit
classic TB symptoms such as chronic cough or hemoptysis.
Low bacterial load: HIV-related immunosuppression often leads to
paucibacillary TB, where the bacterial load is too low to be detected by
conventional microscopy or culture.
High prevalence of extrapulmonary TB: HIV co-infection increases the
likelihood of TB affecting non-pulmonary sites, complicating diagnosis
further
6. Pediatric Tuberculosis
Diagnosing TB in children is notoriously difficult due to non-specific
symptoms, the lower likelihood of sputum production, and the
paucibacillary nature of the disease in this age group. Conventional
diagnostic tests often fail to provide conclusive results, necessitating
reliance on clinical judgment and a history of TB exposure.

7. Drug-Resistant Tuberculosis
The emergence of multidrug-resistant (MDR-TB) and extensively drug-
resistant TB (XDR-TB) has added complexity to TB diagnosis. Detecting
drug resistance requires advanced molecular tests or culture-based drug
susceptibility testing (DST), both of which are resource-intensive and not
universally accessible. Delayed detection of drug resistance can result in
prolonged transmission and inappropriate treatment.

8. Resource Constraints in High-Burden Settings

In regions with high TB prevalence, healthcare systems often face
resource limitations, including:
  Infrastructure Deficits: Lack of well-equipped laboratories and
trained personnel restricts access to advanced diagnostic tools.
 Financial Barriers: The cost of tests like GeneXpert and culture
methods is prohibitive for many patients and healthcare systems.
 Overburdened Facilities: High patient loads in TB-endemic areas can
strain diagnostic services, leading to delays and reduced accuracy.

9. Extrapulmonary Tuberculosis
Extrapulmonary TB, which accounts for a significant proportion of cases,
often presents diagnostic challenges due to its diverse manifestations and
the need for specialized tests. Common forms of extrapulmonary TB
include lymphatic TB, pleural TB, TB meningitis, and skeletal TB.
Diagnosing these forms requires imaging techniques, histopathological
examination, and sometimes invasive procedures, which are not readily
available in many settings.

10. Stigma and Social Barriers

Stigma associated with TB can deter individuals from seeking timely
medical care. Fear of discrimination or ostracization may lead patients to
conceal symptoms or avoid diagnostic testing altogether. Additionally,
lack of awareness about TB symptoms and transmission contributes to
delayed healthcare-seeking behavior.

11. Emerging and Evolving Strains

The continuous evolution of Mycobacterium tuberculosis strains poses
challenges for diagnosis. New strains may exhibit atypical behavior or
resistance to existing diagnostic methods, requiring ongoing research and
development of novel tools.

12. Need for Comprehensive Diagnostic Algorithms

Current diagnostic practices often rely on a single test or approach, which
may not be sufficient given the diverse clinical presentations of TB.
Integrated diagnostic algorithms combining clinical evaluation,
radiological imaging, and laboratory tests are needed to improve
diagnostic accuracy.
Conclusion
Addressing the challenges in TB diagnosis requires a multifaceted
approach. Investment in research and development of rapid, cost-
effective, and accurate diagnostic tools is essential. Strengthening
healthcare infrastructure, increasing access to advanced diagnostic
methods, and training healthcare workers are critical steps. Public health
initiatives should also focus on raising awareness, reducing stigma, and
implementing effective screening programs. By overcoming these
challenges, we can achieve earlier diagnosis, better treatment outcomes,
and progress toward the ultimate goal of TB elimination.

 Limited Access: In rural and low-resource settings, diagnostic

facilities are often unavailable, leading to underreporting and delayed
treatment.

 Cost and Accessibility: Advanced diagnostic tests like GeneXpert are

expensive and may not be available in resource-limited settings.
6. Treatment Protocols for Tuberculosis
6.1 Standard TB Treatment
The first-line treatment for TB consists of a combination of drugs,
including:

Standard Treatment of Tuberculosis (TB)

Tuberculosis (TB) is a serious infectious disease caused by
Mycobacterium tuberculosis. Effective treatment is essential not only for
curing the disease but also for preventing its spread and mitigating the
risk of drug resistance. The treatment of TB involves a standardized
approach that combines multiple drugs to ensure efficacy and minimize
the emergence of resistance. Below is a detailed exploration of the
standard TB treatment protocols, challenges, and considerations.

1. General Principles of TB Treatment

a. Combination Therapy

TB treatment requires the use of multiple drugs to target various bacterial

populations and prevent the development of drug resistance.
Monotherapy is strictly avoided to reduce the risk of resistant strains.
 b. Treatment Duration
c.

The standard duration for TB treatment is 6 months, divided into two

phases:
Intensive Phase: A 2-month period during which four drugs are used
to rapidly reduce the bacterial load.
Continuation Phase: A 4-month period using two drugs to eliminate
any remaining bacteria.


c. Directly Observed Therapy (DOT)

To ensure adherence, the World Health Organization (WHO)
recommends DOT, where healthcare providers observe patients taking
their medications.

d. Individualized Approach
For cases of drug-resistant TB or TB in special populations (e.g.,
children, pregnant women, or individuals with HIV), treatment is tailored
based on specific needs and drug susceptibility testing.

2. First-Line Treatment for Drug-Sensitive TB

The standard regimen for drug-sensitive TB includes the following:
a. Drugs Used

1. Isoniazid (INH): A cornerstone of TB therapy, it targets mycolic

acid synthesis, essential for bacterial cell walls.
 2. Rifampicin (RIF): A potent bactericidal drug that inhibits bacterial
RNA synthesis.
3. Pyrazinamide (PZA): Effective against semi-dormant bacterial
populations within acidic environments, such as those inside
macrophages.
4. Ethambutol (EMB): Included to prevent the emergence of
resistance and has activity against actively replicating bacteria.
b. Standard Regimen
 Intensive Phase: 2 months of INH, RIF, PZA, and EMB.
 Continuation Phase: 4 months of INH and RIF.

c. Dosage
Drug dosages are calculated based on the patient’s weight. Fixed-dose
combination (FDC) tablets are often used to simplify administration and
improve adherence.

3. Treatment of Multidrug-Resistant TB (MDR-TB)

MDR-TB is defined as TB resistant to at least isoniazid and rifampicin.
Treating MDR-TB is more complex, requiring second-line drugs and
prolonged therapy.

a. Drugs Used
1. Fluoroquinolones: Levofloxacin or moxifloxacin.
 2. Second-Line Injectable Agents: Amikacin, kanamycin, or
capreomycin.
3. Other Oral Agents: Linezolid, bedaquiline, delamanid, and
cycloserine.
b. Regimen Duration
Treatment typically lasts 18-24 months, depending on the severity and
response to therapy. WHO also recommends shorter MDR-TB regimens
(9-12 months) in select cases.

c. Challenges
 Higher toxicity and side effects compared to first-line drugs.
 Increased cost and limited availability of second-line drugs.


4. Treatment of Extensively Drug-Resistant TB (XDR-TB)

XDR-TB is resistant to isoniazid, rifampicin, fluoroquinolones, and at
least one second-line injectable agent. Treatment is highly individualized
and depends on drug susceptibility testing.

a. Drugs Used
1. Bedaquiline
2. Linezolid
 3. Clofazimine
4. Pretomanid (in select cases)
b. Regimen Duration
Typically 20-24 months, with close monitoring for adverse effects and
treatment efficacy.

c. Outcomes
XDR-TB treatment outcomes are less favorable, with cure rates
significantly lower than for drug-sensitive TB.

5. TB Treatment in Special Populations

a. Children
Children often receive the same drugs as adults but in weight-based
dosages.
Pediatric formulations are available for easier administration.
b. Pregnant Women
 First-line drugs, except for streptomycin, are generally safe in
pregnancy.
 Pyrazinamide is often avoided due to limited safety data.
c. HIV Co-Infection
 Co-administration of TB and antiretroviral therapy (ART) is essential.
  Rifampicin interacts with several ART drugs, necessitating regimen
adjustments.


d. Patients with Liver Disease

 Liver function tests guide drug selection to minimize hepatotoxicity.
 Regimens may exclude or reduce the dosage of isoniazid, rifampicin,
or pyrazinamide.

6. Monitoring and Managing Side Effects

a. Common Side Effects
1. Hepatotoxicity: Caused by isoniazid, rifampicin, and pyrazinamide.
2. Gastrointestinal Symptoms: Nausea, vomiting, and diarrhea.
3. Peripheral Neuropathy: Associated with isoniazid, often managed
with vitamin B6 supplementation.
4. Ototoxicity: Seen with second-line injectable agents.
b. Monitoring Protocols
 Regular liver function tests (LFTs) for hepatotoxicity.
 Baseline and periodic hearing tests for ototoxicity.
 Close clinical monitoring for adherence and side effects.
7. Challenges in TB Treatment
a. Non-Adherence
 Prolonged treatment duration and side effects often lead to poor
adherence.
 DOT and patient education programs are critical to improving
compliance.


b. Drug Resistance
 Incomplete or improper treatment contributes to the emergence of
MDR-TB and XDR-TB.


c. Resource Constraints
 In many high-burden countries, access to diagnostics, drugs, and
healthcare services is limited.


d. Stigma and Social Barriers

 Fear of stigma may deter patients from seeking treatment or adhering
to therapy.

8. Emerging Approaches in TB Treatment

a. Shorter Regimens
 Research into shorter regimens aims to improve adherence and
outcomes.
 The 4-month rifapentine-moxifloxacin regimen is one promising
example.


b. New Drugs
 Drugs like bedaquiline and delamanid offer hope for resistant TB
cases.


c. Vaccines and Preventive Therapy

 Expanded use of preventive therapy for latent TB and development of
effective vaccines are critical to global TB control efforts.

Conclusion
The standard treatment of TB is highly effective when administered
properly. However, challenges such as drug resistance, adherence issues,
and resource constraints necessitate continuous efforts to optimize
regimens, improve access to care, and develop new tools. By addressing
these challenges, healthcare systems can move closer to the goal of
eradicating TB globally.

 Isoniazid (INH)

 Rifampicin (RIF)

 Pyrazinamide (PZA)

 Ethambutol (EMB)

These drugs are typically taken for a 6-month regimen. The treatment
is highly effective for drug-sensitive TB.
6.2 Treatment for Drug-Resistant Tuberculosis
Multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB
(XDR-TB) require more complex and prolonged treatment regimens,
often lasting up to 18-24 months. The treatment includes second-line
drugs such as:
Bedaquiline
Linezolid
Clofazimine

These treatments are more expensive and have more side effects, making
them less accessible in many parts of the world.
6.3 Challenges in Treatment
Drug Resistance: MDR-TB and XDR-TB present significant
challenges, with resistance to first-line drugs complicating treatment.
Adherence to Treatment: Patients must complete the entire treatment
regimen to avoid relapse and resistance development. Poor adherence
to treatment is a significant issue.
7. Public Health Perspective
7.1 Global Efforts and the End TB Strategy

The World Health Organization (WHO) launched the "End TB Strategy"

with the goal to end TB by 2030. This strategy aims to reduce TB deaths
by 90%, TB incidence by 80%, and eliminate catastrophic costs for
affected families. The strategy focuses on:

 Early diagnosis and effective treatment.

 Providing support to high-risk populations.
 Improving access to new and better diagnostics and treatments.

7.2 National TB Programs

Countries like India, China, and South Africa have national TB programs
aimed at early detection and treatment. The Indian government offers
free diagnosis and treatment through its National Tuberculosis
Elimination Program (NTEP).

7.3 Vaccination
The Bacillus Calmette-Guérin (BCG) vaccine is widely used to prevent
TB in children. However, its efficacy in adults is limited. New vaccine
candidates are being researched to provide better protection against TB.
8. TB in Special Populations
8.1 TB and HIV Co-Infection
HIV significantly increases the risk of developing TB. HIV weakens the
immune system, making it harder for the body to fight off TB. TB is one
of the leading causes of death in people living with HIV. Co-infection
complicates the management and treatment of both diseases.
8.2 Pediatric TB
In children, TB can present with atypical symptoms such as fever, weight
loss, and fatigue. Pediatric TB is often misdiagnosed, leading to delays in
treatment.
8.3 Pregnant Women and TB
TB during pregnancy can lead to complications, including preterm birth,
low birth weight, and the transmission of TB to the infant. The treatment
of TB during pregnancy is complex, as certain drugs can affect the fetus.
9. Challenges in TB Eradication
9.1 Socioeconomic Barriers
Poverty, malnutrition, and overcrowded living conditions contribute to
the spread of TB. Many people in low-income countries have limited
access to healthcare, leading to delayed diagnosis and treatment.

9.2 Drug Resistance

The rise of MDR-TB and XDR-TB is a major obstacle in the fight
against TB. The misuse of antibiotics and incomplete treatment regimens
contribute to the development of drug-resistant strains.

9.3 Stigma
The social stigma associated with TB often prevents individuals from
seeking treatment. This stigma can also affect family members and
caregivers of TB patients.
10. Research and Innovations
10.1 TB Vaccines
New vaccines are in development, including the M72/AS01E vaccine,
which shows promise in preventing both pulmonary and extrapulmonary
TB.
10.2 Drug Research
Several new drugs, such as bedaquiline, delamanid, and linezolid, are
being investigated for their efficacy in treating MDR-TB and XDR-TB.
These drugs offer hope for better treatment outcomes.
10.3 Diagnostic Innovations
Artificial intelligence (AI) and machine learning models are being
explored for early diagnosis of TB through imaging and symptom
tracking. These innovations aim to detect TB more accurately and at an
earlier stage.

11. Case Studies

Case 1: Peru’s Community-Based Approach
In Peru, a community-based approach to TB management significantly
reduced TB incidence. The strategy included early detection, community
involvement, and education.

1. A 45-year-old male underwent exploratory laparotomy

after presenting with abdominal pain, fever, anorexia, night
sweats, and weight loss, over one month (Fig. 1). He
provided no history of close contact with TB patients,
although he had history of chronic recurrent cough. This
information raised a high suspicion of TB. A diagnosis of
small bowel obstruction secondary to a caecal mass was
made and histopathology of omental biopsy confirmed a
chronic granulomatous inflammation caused by TB without
any signs of malignancy (Fig. 2). He underwent a right
hemicolectomy and anastomosis end-to-side to the
transverse ileocolical region. The physical examination on
subsequent presentation showed no adventitious breath
sounds, an abdominal scar from the laparotomy, without
organomegaly. However, infiltrates in both apices was
shown in his chest x-ray, and an abdominal CT-scan prior
his surgery was remarkable for signs of bowel obstruction.
He was anemic with a haemoglobin of 9.4 g%. Sputum
gram-stain revealed positive results of AFB
and Diplococcus. He was then diagnosed with pulmonary
and intestinal TB, therefore treated with 6 months of ATD.
Case 2: Rwanda’s Integrated TB-HIV Care
Rwanda integrated TB and HIV care, leading to a significant reduction in
TB-related deaths among HIV-positive individuals. This approach
demonstrates the importance of collaborative healthcare efforts.
An 11-month-old Iranian Turk boy was referred to Loghman
Hakim Hospital for progressive limb weakness and loss of
previously attained developmental milestones for the past
2 months. He also had persistent fever and loss of consciousness
for about 14 to 21 days (please write how many days). He was
born at 35 weeks of gestation by cesarean section with normal
birth weight (2650 g), length (50 cm), and head circumference
(35 cm). He received BCG and other routine immunizations.
His neonatal period, development up to 9 months, and family
history were unremarkable. His parents noticed progressive
weakness of all four limbs and loss of head control along with
the inability to creep or crawl, at 11 months of age. He would
constantly cry and be irritable. Subsequently, he was
unresponsiveness and lost consciousness. For these complaints,
he was taken to a hospital where he had been diagnosed with
hydrocephalus possibly due to acute bacterial meningitis based
on a CT scan and MRI imaging of the brain. He was treated
with acetazolamide, ceftriaxone, corticosteroid, and antipyretic
for 11 days.
The patient was referred to our hospital due to clinical
deterioration and the onset of new symptoms. Additionally, his
parents noted convergence deviation of the eyes and flexion of
the lower limbs when held upright. He was ill, febrile (38.6
degrees Celsius axillary), lethargic, and continuously crying. He
lost head control and was unable to crawl which he was doing
earlier. On physical examination at our center, the anterior
fontanel was bulging and there was neck stiffness. Left 6th
cranial nerve paresis and quadriparesis (3/5 for both upper and
lower limbs) was present. Hyperreflexia (DTR 3/4) and
extensor plantar reflexes bilaterally were observed. Right basal
ganglia hypodensity consistent with infarct-induced ischemia
along with four ventricular hydrocephalus could be noticed in
brain CT scans without contrast injection (Figs. 1 and 2). Brain
MRI revealed severe four-ventricular hydrocephalus with peri-
ependymal edema associated with significant leptomeningeal
enhancement of the intracranial cisterns and sulci (see
Additional files 1 and 2). There were some enhancing foci at
bilateral thalami and pons. Based on hydrocephalus, basal
ganglia infarction, and the leptomeningeal enhancement, it was
decided to perform endoscopic third ventriculostomy (ETV)
(and leptomeningeal biopsy) as the diagnostic and therapeutic
approaches. During ETV, diffuse thickening of the floor and
lateral walls of the 3rd ventricle and also a cobblestone
appearance in the form of multiple white patchy lesions was
detected on the floor of the 3rd ventricle (Fig. 3). CSF obtained
during ETV suggested TB meningitis (protein: 183 mg/dL
(normal range: 15–45 mg/dl), glucose 56 mg/dL (normal range:
45–80 mg/dl), blood glucose: 109 mg/dL (normal range: 70–
179 mg/dl), WBC: 55/mm3 (normal range: 0–25/mm3), RBC:
0/mm3 (normal range: 0–5/mm3), PMN: 10%, MN: 90%);
Therefore, empiric three-drug regimen with isoniazid,
pyrazinamide, and rifampin was started. Finally, CSF analysis
revealed acid-fast bacilli in Ziehl–Neelsen staining, and
Mycobacterium tuberculosis was detected by polymerase chain
reaction (PCR). The histopathologic examination revealed
multiple well demarcated granulomas composed of epithelioid
histiocytes Langerhans cells and foreign body types
multinucleated giant cells and areas of acellular necrosis
(Figs. 4 and 5), confirming the diagnosis of TB.
12. Conclusion and Recommendations

12.1 Summary
Tuberculosis remains a major global health challenge despite significant
progress in treatment and prevention. MDR-TB and XDR-TB present
serious threats to the effectiveness of current treatment protocols.
12.2 Recommendations
Strengthen healthcare infrastructure in low-income countries.
Improve access to advanced diagnostics and treatments.
Increase funding for TB research and vaccine development.

13. References
WHO Global Tuberculosis Report 2023.
 Journal articles on TB and drug resistance.
 Textbooks on microbiology and infectious diseases.
 1.
 Lönnroth K, Migliori GB, Abubakar I, D'Ambrosio L, de
Vries G, Diel R, Douglas P, Falzon D, Gaudreau MA, Goletti
D, González Ochoa ER, LoBue P, Matteelli A, Njoo H,
Solovic I, Story A, Tayeb T, van der Werf MJ, Weil D,
Zellweger JP, Abdel Aziz M, Al Lawati MR, Aliberti S,
Arrazola de Oñate W, Barreira D, Bhatia V, Blasi F, Bloom
A, Bruchfeld J, Castelli F, Centis R, Chemtob D, Cirillo DM,
Colorado A, Dadu A, Dahle UR, De Paoli L, Dias HM,
Duarte R, Fattorini L, Gaga M, Getahun H, Glaziou P,
Goguadze L, Del Granado M, Haas W, Järvinen A, Kwon
GY, Mosca D, Nahid P, Nishikiori N, Noguer I, O'Donnell J,
Pace-Asciak A, Pompa MG, Popescu GG, Robalo Cordeiro C,
Rønning K, Ruhwald M, Sculier JP, Simunović A, Smith-
Palmer A, Sotgiu G, Sulis G, Torres-Duque CA, Umeki K,
Uplekar M, van Weezenbeek C, Vasankari T, Vitillo RJ,
Voniatis C, Wanlin M, Raviglione MC. Towards tuberculosis
elimination: an action framework for low-incidence
countries. Eur Respir J. 2015 Apr;45(4):928-52. [PMC free
article] [PubMed]
 2.
 Cole ST. Learning from the genome sequence of
Mycobacterium tuberculosis H37Rv. FEBS Lett. 1999 Jun
04;452(1-2):7-10. [PubMed]
 3.
 Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris
D, Gordon SV, Eiglmeier K, Gas S, Barry CE, Tekaia F,
Badcock K, Basham D, Brown D, Chillingworth T, Connor R,
Davies R, Devlin K, Feltwell T, Gentles S, Hamlin N,
Holroyd S, Hornsby T, Jagels K, Krogh A, McLean J, Moule
S, Murphy L, Oliver K, Osborne J, Quail MA, Rajandream
MA, Rogers J, Rutter S, Seeger K, Skelton J, Squares R,
Squares S, Sulston JE, Taylor K, Whitehead S, Barrell BG.
Deciphering the biology of Mycobacterium tuberculosis from
the complete genome sequence. Nature. 1998 Jun
11;393(6685):537-44. [PubMed]
 4.
 Lalvani A, Whitworth HS. Progress in interferon-gamma
release assay development and applications: an unfolding
story of translational research. Ann Transl Med. 2019
Jul;7(Suppl 3):S128. [PMC free article] [PubMed]
 5.
 MacLean E, Kohli M, Weber SF, Suresh A, Schumacher SG,
Denkinger CM, Pai M. Advances in Molecular Diagnosis of
 Tuberculosis. J Clin Microbiol. 2020 Sep 22;58(10) [PMC
free article] [PubMed]
 6.
 WHO consolidated guidelines on tuberculosis: Module 3:
Diagnosis – Tests for tuberculosis infection. World Health
Organization; Geneva: 2022. [PubMed]
 7.
 D'Ambrosio L, Centis R, Tiberi S, Tadolini M, Dalcolmo M,
Rendon A, Esposito S, Migliori GB. Delamanid and
bedaquiline to treat multidrug-resistant and extensively drug-
resistant tuberculosis in children: a systematic review. J
Thorac Dis. 2017 Jul;9(7):2093-2101. [PMC free article]
[PubMed]
 8.
 Sterling TR, Njie G, Zenner D, Cohn DL, Reves R, Ahmed A,
Menzies D, Horsburgh CR, Crane CM, Burgos M, LoBue P,
Winston CA, Belknap R. Guidelines for the Treatment of
Latent Tuberculosis Infection: Recommendations from the
National Tuberculosis Controllers Association and CDC,
2020. MMWR Recomm Rep. 2020 Feb 14;69(1):1-11. [PMC
free article] [PubMed]
 9.
 Bigi MM, Forrellad MA, García JS, Blanco FC, Vázquez CL,
Bigi F. An update on Mycobacterium
 tuberculosis lipoproteins. Future Microbiol. 2023
Dec;18:1381-1398. [PubMed]
 10.
 Warner DF, Koch A, Mizrahi V. Diversity and disease
pathogenesis in Mycobacterium tuberculosis. Trends
Microbiol. 2015 Jan;23(1):14-21. [PubMed]
 11.
 Schildknecht KR, Pratt RH, Feng PI, Price SF, Self JL.
Tuberculosis - United States, 2022. MMWR Morb Mortal
Wkly Rep. 2023 Mar 24;72(12):297-303. [PMC free article]
[PubMed]
 12.
 WHO consolidated guidelines on tuberculosis: Module 3:
diagnosis – rapid diagnostics for tuberculosis detection
[Internet]. World Health Organization; Geneva: 2021.
[PubMed]
 13.
 Karnan A, Jadhav U, Ghewade B, Ledwani A, Shivashankar
P. A Comprehensive Review on Long vs. Short Regimens in
Multidrug-Resistant Tuberculosis (MDR-TB) Under
Programmatic Management of Drug-Resistant Tuberculosis
(PMDT). Cureus. 2024 Jan;16(1):e52706. [PMC free article]
[PubMed]
 14.
 Drain PK, Bajema KL, Dowdy D, Dheda K, Naidoo K,
Schumacher SG, Ma S, Meermeier E, Lewinsohn DM,
Sherman DR. Incipient and Subclinical Tuberculosis: a
Clinical Review of Early Stages and Progression of
Infection. Clin Microbiol Rev. 2018 Oct;31(4) [PMC free
article] [PubMed]
 15.
 Elkington PT, Friedland JS. Permutations of time and place in
tuberculosis. Lancet Infect Dis. 2015 Nov;15(11):1357-
60. [PMC free article] [PubMed]
 16.
 Pai M, Behr MA, Dowdy D, Dheda K, Divangahi M, Boehme
CC, Ginsberg A, Swaminathan S, Spigelman M, Getahun H,
Menzies D, Raviglione M. Tuberculosis. Nat Rev Dis
Primers. 2016 Oct 27;2:16076. [PubMed]
 17.
 Smith I. Mycobacterium tuberculosis pathogenesis and
molecular determinants of virulence. Clin Microbiol
Rev. 2003 Jul;16(3):463-96. [PMC free article] [PubMed]
 18.
 Russell DG, Cardona PJ, Kim MJ, Allain S, Altare F. Foamy
macrophages and the progression of the human tuberculosis
granuloma. Nat Immunol. 2009 Sep;10(9):943-8. [PMC free
article] [PubMed]
 19.
 Lawn SD, Wood R, Wilkinson RJ. Changing concepts of
"latent tuberculosis infection" in patients living with HIV
infection. Clin Dev Immunol. 2011;2011 [PMC free article]
[PubMed]
 20.
 Golden MP, Vikram HR. Extrapulmonary tuberculosis: an
overview. Am Fam Physician. 2005 Nov 01;72(9):1761-
8. [PubMed]
 21.
 Hoa NB, Sy DN, Nhung NV, Tiemersma EW, Borgdorff
MW, Cobelens FG. National survey of tuberculosis
prevalence in Viet Nam. Bull World Health Organ. 2010
Apr;88(4):273-80. [PMC free article] [PubMed]
 22.
 Wood R, Middelkoop K, Myer L, Grant AD, Whitelaw A,
Lawn SD, Kaplan G, Huebner R, McIntyre J, Bekker LG.
Undiagnosed tuberculosis in a community with high HIV
prevalence: implications for tuberculosis control. Am J Respir
Crit Care Med. 2007 Jan 01;175(1):87-93. [PMC free article]
[PubMed]
 23.
 Kendall EA, Kitonsa PJ, Nalutaaya A, Erisa KC, Mukiibi J,
Nakasolya O, Isooba D, Baik Y, Robsky KO, Kato-Maeda M,
 Cattamanchi A, Katamba A, Dowdy DW. The Spectrum of
Tuberculosis Disease in an Urban Ugandan Community and
Its Health Facilities. Clin Infect Dis. 2021 Jun
15;72(12):e1035-e1043. [PMC free article] [PubMed]
 24.
 Urbanowski ME, Ordonez AA, Ruiz-Bedoya CA, Jain SK,
Bishai WR. Cavitary tuberculosis: the gateway of disease
transmission. Lancet Infect Dis. 2020 Jun;20(6):e117-
e128. [PMC free article] [PubMed]
 25.
 Kashyap S, Solanki A. Challenges in endobronchial
tuberculosis: from diagnosis to management. Pulm
Med. 2014;2014:594806. [PMC free article] [PubMed]
 26.
 He W, Tan Y, Song Z, Liu B, Wang Y, He P, Xia H, Huang F,
Liu C, Zheng H, Pei S, Liu D, Ma A, Cao X, Zhao B, Ou X,
Wang S, Zhao Y. Endogenous relapse and exogenous
reinfection in recurrent pulmonary tuberculosis: A
retrospective study revealed by whole genome
sequencing. Front Microbiol. 2023;14:1115295. [PMC free
article] [PubMed]
 27.
 Hamada Y, Getahun H, Tadesse BT, Ford N. HIV-associated
tuberculosis. Int J STD AIDS. 2021 Aug;32(9):780-
790. [PMC free article] [PubMed]
 28.
 Kwan CK, Ernst JD. HIV and tuberculosis: a deadly human
syndemic. Clin Microbiol Rev. 2011 Apr;24(2):351-76. [PMC
free article] [PubMed]
 29.
 Bruchfeld J, Correia-Neves M, Källenius G. Tuberculosis and
HIV Coinfection. Cold Spring Harb Perspect Med. 2015 Feb
26;5(7):a017871. [PMC free article] [PubMed]
 30.
 Getahun H, Kittikraisak W, Heilig CM, Corbett EL, Ayles H,
Cain KP, Grant AD, Churchyard GJ, Kimerling M, Shah S,
Lawn SD, Wood R, Maartens G, Granich R, Date AA, Varma
JK. Development of a standardized screening rule for
tuberculosis in people living with HIV in resource-constrained
settings: individual participant data meta-analysis of
observational studies. PLoS Med. 2011 Jan
18;8(1):e1000391. [PMC free article] [PubMed]
 31.
 Gadkowski LB, Stout JE. Cavitary pulmonary disease. Clin
Microbiol Rev. 2008 Apr;21(2):305-33, table of
contents. [PMC free article] [PubMed]
 32.
 Davies PD, Pai M. The diagnosis and misdiagnosis of
tuberculosis. Int J Tuberc Lung Dis. 2008 Nov;12(11):1226-
34. [PubMed]
 33.
 Pagaduan JV, Altawallbeh G. Advances in TB testing. Adv
Clin Chem. 2023;115:33-62. [PMC free article] [PubMed]
 34.
 Lewinsohn DM, Leonard MK, LoBue PA, Cohn DL, Daley
CL, Desmond E, Keane J, Lewinsohn DA, Loeffler AM,
Mazurek GH, O'Brien RJ, Pai M, Richeldi L, Salfinger M,
Shinnick TM, Sterling TR, Warshauer DM, Woods GL.
Official American Thoracic Society/Infectious Diseases
Society of America/Centers for Disease Control and
Prevention Clinical Practice Guidelines: Diagnosis of
Tuberculosis in Adults and Children. Clin Infect Dis. 2017 Jan
15;64(2):111-115. [PMC free article] [PubMed]
 35.
 Brodie D, Schluger NW. The diagnosis of tuberculosis. Clin
Chest Med. 2005 Jun;26(2):247-71, vi. [PubMed]
 36.
 Skoura E, Zumla A, Bomanji J. Imaging in tuberculosis. Int J
Infect Dis. 2015 Mar;32:87-93. [PubMed]
 37.
 Carranza C, Pedraza-Sanchez S, de Oyarzabal-Mendez E,
Torres M. Diagnosis for Latent Tuberculosis Infection: New
Alternatives. Front Immunol. 2020;11:2006. [PMC free
article] [PubMed]
 38.
 Esmail H, Barry CE, Young DB, Wilkinson RJ. The ongoing
challenge of latent tuberculosis. Philos Trans R Soc Lond B
Biol Sci. 2014;369(1645):20130437. [PMC free article]
[PubMed]
 39.
 Menzies D, Gardiner G, Farhat M, Greenaway C, Pai M.
Thinking in three dimensions: a web-based algorithm to aid
the interpretation of tuberculin skin test results. Int J Tuberc
Lung Dis. 2008 May;12(5):498-505. [PubMed]
 40.
 Bomanji JB, Gupta N, Gulati P, Das CJ. Imaging in
tuberculosis. Cold Spring Harb Perspect Med. 2015 Jan
20;5(6) [PMC free article] [PubMed]
 41.
 Automated Real-Time Nucleic Acid Amplification
Technology for Rapid and Simultaneous Detection of
Tuberculosis and Rifampicin Resistance: Xpert MTB/RIF
Assay for the Diagnosis of Pulmonary and Extrapulmonary
 TB in Adults and Children: Policy Update. World Health
Organization; Geneva: 2013. [PubMed]
 42.
 da Silva MP, Cassim N, Ndlovu S, Marokane PS, Radebe M,
Shapiro A, Scott LE, Stevens WS. More Than a Decade of
®
GeneXpert Mycobacterium tuberculosis/Rifampicin (Ultra)
Testing in South Africa: Laboratory Insights from Twenty-
Three Million Tests. Diagnostics (Basel). 2023 Oct
19;13(20) [PMC free article] [PubMed]
 43.
 Dorman SE, Schumacher SG, Alland D, Nabeta P, Armstrong
DT, King B, Hall SL, Chakravorty S, Cirillo DM, Tukvadze
N, Bablishvili N, Stevens W, Scott L, Rodrigues C, Kazi MI,
Joloba M, Nakiyingi L, Nicol MP, Ghebrekristos Y, Anyango
I, Murithi W, Dietze R, Lyrio Peres R, Skrahina A, Auchynka
V, Chopra KK, Hanif M, Liu X, Yuan X, Boehme CC, Ellner
JJ, Denkinger CM., study team. Xpert MTB/RIF Ultra for
detection of Mycobacterium tuberculosis and rifampicin
resistance: a prospective multicentre diagnostic accuracy
study. Lancet Infect Dis. 2018 Jan;18(1):76-84. [PMC free
article] [PubMed]
 44.
 Procop GW. Laboratory Diagnosis and Susceptibility Testing
for Mycobacterium tuberculosis. Microbiol Spectr. 2016
Dec;4(6) [PubMed]
 45.
 Mathew P, Kuo YH, Vazirani B, Eng RH, Weinstein MP. Are
three sputum acid-fast bacillus smears necessary for
discontinuing tuberculosis isolation? J Clin Microbiol. 2002
Sep;40(9):3482-4. [PMC free article] [PubMed]
 46.
 Wu RI, Mark EJ, Hunt JL. Staining for acid-fast bacilli in
surgical pathology: practice patterns and variations. Hum
Pathol. 2012 Nov;43(11):1845-51. [PubMed]
 47.
 Theron G, Venter R, Calligaro G, Smith L, Limberis J,
Meldau R, Chanda D, Esmail A, Peter J, Dheda K. Xpert
MTB/RIF Results in Patients With Previous Tuberculosis:
Can We Distinguish True From False Positive Results? Clin
Infect Dis. 2016 Apr 15;62(8):995-1001. [PMC free article]
[PubMed]
 48.
 Ngangue YR, Mbuli C, Neh A, Nshom E, Koudjou A, Palmer
D, Ndi NN, Qin ZZ, Creswell J, Mbassa V, Vuchas C, Sander
M. Diagnostic Accuracy of the Truenat MTB Plus Assay and
Comparison with the Xpert MTB/RIF Assay to Detect
 Tuberculosis among Hospital Outpatients in Cameroon. J Clin
Microbiol. 2022 Aug 17;60(8):e0015522. [PMC free article]
[PubMed]
 49.
 Notomi T, Mori Y, Tomita N, Kanda H. Loop-mediated
isothermal amplification (LAMP): principle, features, and
future prospects. J Microbiol. 2015 Jan;53(1):1-5. [PubMed]
 50.
 Bulterys MA, Wagner B, Redard-Jacot M, Suresh A, Pollock
NR, Moreau E, Denkinger CM, Drain PK, Broger T. Point-
Of-Care Urine LAM Tests for Tuberculosis Diagnosis: A
Status Update. J Clin Med. 2019 Dec 31;9(1) [PMC free
article] [PubMed]
 51.
 Pillay S, de Vos M, Sohn H, Ghebrekristos Y, Dolby T,
Warren RM, Theron G. To Test or Not? Xpert MTB/RIF as an
Alternative to Smear Microscopy to Guide Line Probe Assay
Testing for Drug-Resistant Tuberculosis. J Clin
Microbiol. 2023 Jul 20;61(7):e0001723. [PMC free article]
[PubMed]
 52.
 Aggarwal AN, Agarwal R, Sehgal IS, Dhooria S. Adenosine
deaminase for diagnosis of tuberculous pleural effusion: A
 systematic review and meta-analysis. PLoS
One. 2019;14(3):e0213728. [PMC free article] [PubMed]
 53.
 Prasad MK, Kumar A, Nalini N, Kumar P, Mishra B, Lata D,
Ashok C, Kumar D, Marandi S, Kumar D, Singh S, Mahajan
M. Diagnostic Accuracy of Cerebrospinal Fluid (CSF)
Adenosine Deaminase (ADA) for Tuberculous Meningitis
(TBM) in Adults: A Systematic Review and Meta-
Analysis. Cureus. 2023 Jun;15(6):e39896. [PMC free article]
[PubMed]
 54.
 Tao L, Ning HJ, Nie HM, Guo XY, Qin SY, Jiang HX.
Diagnostic value of adenosine deaminase in ascites for
tuberculosis ascites: a meta-analysis. Diagn Microbiol Infect
Dis. 2014 May;79(1):102-7. [PubMed]
 55.
 Sadowski C, Belknap R, Holland DP, Moro RN, Chen MP,
Wright A, Millet JP, Caylà JA, Scott NA, Borisov A, Gandhi
NR. Symptoms and Systemic Drug Reactions in Persons
Receiving Weekly Rifapentine Plus Isoniazid (3HP)
Treatment for Latent Tuberculosis Infection. Clin Infect
Dis. 2023 Jun 16;76(12):2090-2097. [PMC free article]
[PubMed]
 56.
 WHO consolidated guidelines on tuberculosis: tuberculosis
preventive treatment: Module 1: prevention [Internet]. World
Health Organization; Geneva: 2020. [PubMed]
 57.
 Suryavanshi N, Murrill M, Gupta A, Hughes M, Hesseling A,
Kim S, Naini L, Jones L, Smith B, Gupte N, Dawson R, Mave
V, Meshram S, Mendoza-Ticona A, Sanchez J, Kumarasamy
N, Comins K, Conradie F, Shenje J, Nerette Fontain S,
Garcia-Prats A, Asmelash A, Nedsuwan S, Mohapi L, Lalloo
U, Cristina Garcia Ferreira A, Okeyo E, Swindells S,
Churchyard G, Shah NS. Willingness to Take Multidrug-
resistant Tuberculosis (MDR-TB) Preventive Therapy Among
Adult and Adolescent Household Contacts of MDR-TB Index
Cases: An International Multisite Cross-sectional Study. Clin
Infect Dis. 2020 Jan 16;70(3):436-445. [PMC free article]
[PubMed]
 58.
 Kasaie P, Pennington J, Gupta A, Dowdy DW, Kendall EA.
Trials underestimate the impact of preventive treatment for
household contacts exposed to multidrug-resistant
tuberculosis: a simulation study. medRxiv. 2023 Feb
08; [PubMed]
 59.
 Krishnan S, Wu X, Kim S, McIntire K, Naini L, Hughes MD,
Dawson R, Mave V, Gaikwad S, Sanchez J, Mendoza-Ticona
A, Gonzales P, Comins K, Shenje J, Fontain SN, Omozoarhe
A, Mohapi L, Lalloo UG, Garcia Ferreira AC, Mugah C,
Harrington M, Shah NS, Hesseling AC, Churchyard G,
Swindells S, Gupta A., AIDS Clinical Trials Group
A5300/International Maternal Pediatric Adolescent AIDS
Clinical Trials I2003 Protecting Households on Exposure to
Newly Diagnosed Index Multidrug-resistant Tuberculosis
Patients Feasibility Study Team* (Additional study group
members are listed in the Acknowledgment section). 1-Year
Incidence of Tuberculosis Infection and Disease Among
Household Contacts of Rifampin- and Multidrug-Resistant
Tuberculosis. Clin Infect Dis. 2023 Sep 18;77(6):892-
900. [PMC free article] [PubMed]
 60.
 Adjobimey M, Behr MA, Menzies D. Individualized
Treatment Duration in Tuberculosis Treatment: Precision
versus Simplicity. Am J Respir Crit Care Med. 2021 Nov
01;204(9):1013-1014. [PMC free article] [PubMed]
 61.
 Imperial MZ, Phillips PPJ, Nahid P, Savic RM. Precision-
Enhancing Risk Stratification Tools for Selecting Optimal
Treatment Durations in Tuberculosis Clinical Trials. Am J
 Respir Crit Care Med. 2021 Nov 01;204(9):1086-1096. [PMC
free article] [PubMed]
 62.
 Carr W, Kurbatova E, Starks A, Goswami N, Allen L,
Winston C. Interim Guidance: 4-Month Rifapentine-
Moxifloxacin Regimen for the Treatment of Drug-Susceptible
Pulmonary Tuberculosis - United States, 2022. MMWR Morb
Mortal Wkly Rep. 2022 Feb 25;71(8):285-289. [PubMed]
 63.
 Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K,
Dooley KE, Engle M, Goldberg SV, Phan HTT, Hakim J,
Johnson JL, Lourens M, Martinson NA, Muzanyi G,
Narunsky K, Nerette S, Nguyen NV, Pham TH, Pierre S,
Purfield AE, Samaneka W, Savic RM, Sanne I, Scott NA,
Shenje J, Sizemore E, Vernon A, Waja Z, Weiner M,
Swindells S, Chaisson RE., AIDS Clinical Trials Group.
Tuberculosis Trials Consortium. Four-Month Rifapentine
Regimens with or without Moxifloxacin for Tuberculosis. N
Engl J Med. 2021 May 06;384(18):1705-1718. [PMC free
article] [PubMed]
 64.
 Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL,
Cattamanchi A, Chaisson LH, Chaisson RE, Daley CL,
Grzemska M, Higashi JM, Ho CS, Hopewell PC, Keshavjee
 SA, Lienhardt C, Menzies R, Merrifield C, Narita M, O'Brien
R, Peloquin CA, Raftery A, Saukkonen J, Schaaf HS, Sotgiu
G, Starke JR, Migliori GB, Vernon A. Official American
Thoracic Society/Centers for Disease Control and
Prevention/Infectious Diseases Society of America Clinical
Practice Guidelines: Treatment of Drug-Susceptible
Tuberculosis. Clin Infect Dis. 2016 Oct 01;63(7):e147-
e195. [PMC free article] [PubMed]
 65.
 Sotgiu G, Centis R, D'ambrosio L, Migliori GB. Tuberculosis
treatment and drug regimens. Cold Spring Harb Perspect
Med. 2015 Jan 08;5(5):a017822. [PMC free article] [PubMed]
 66.
 Stillo J, Frick M, Galarza J, Kondratyuk S, Makone A,
McKenna L, Vandevelde W, Winarni P, Agbassi P.
Addressing the needs of people with extensively drug-
resistant TB through pre-approval access to drugs and
research. Public Health Action. 2023 Dec;13(4):126-
129. [PMC free article] [PubMed]
 67.
 Gupta A, Juneja S, Babawale V, Rustam Majidovich N,
Ndjeka N, Thi Mai Nguyen P, Nargiza Nusratovna P, Robert
Omanito D, Tiara Pakasi T, Terleeva Y, Toktogonova A,
Waheed Y, Myint Z, Yanlin Z, Sahu S. Global adoption of 6-
 month drug-resistant TB regimens: Projected uptake by
2026. PLoS One. 2024;19(1):e0296448. [PMC free article]
[PubMed]
 68.
 WHO consolidated guidelines on tuberculosis: Module 4:
Treatment - Drug-resistant tuberculosis treatment
[Internet]. World Health Organization; Geneva: 2020.
[PubMed]
 69.
 Nahid P, Mase SR, Migliori GB, Sotgiu G, Bothamley GH,
Brozek JL, Cattamanchi A, Cegielski JP, Chen L, Daley CL,
Dalton TL, Duarte R, Fregonese F, Horsburgh CR, Ahmad
Khan F, Kheir F, Lan Z, Lardizabal A, Lauzardo M, Mangan
JM, Marks SM, McKenna L, Menzies D, Mitnick CD, Nilsen
DM, Parvez F, Peloquin CA, Raftery A, Schaaf HS, Shah NS,
Starke JR, Wilson JW, Wortham JM, Chorba T, Seaworth B.
Treatment of Drug-Resistant Tuberculosis. An Official
ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am J
Respir Crit Care Med. 2019 Nov 15;200(10):e93-e142. [PMC
free article] [PubMed]
 70.
 World Health Organization BCG vaccine: WHO position
paper, February 2018 - Recommendations. Vaccine. 2018 Jun
07;36(24):3408-3410. [PubMed]
 71.
 Andersen P, Doherty TM. The success and failure of BCG -
implications for a novel tuberculosis vaccine. Nat Rev
Microbiol. 2005 Aug;3(8):656-62. [PubMed]
 72.
 Qu M, Zhou X, Li H. BCG vaccination strategies against
tuberculosis: updates and perspectives. Hum Vaccin
Immunother. 2021 Dec 02;17(12):5284-5295. [PMC free
article] [PubMed]
 73.
 Lewinsohn DM, Leonard MK, LoBue PA, Cohn DL, Daley
CL, Desmond E, Keane J, Lewinsohn DA, Loeffler AM,
Mazurek GH, O'Brien RJ, Pai M, Richeldi L, Salfinger M,
Shinnick TM, Sterling TR, Warshauer DM, Woods GL.
Official American Thoracic Society/Infectious Diseases
Society of America/Centers for Disease Control and
Prevention Clinical Practice Guidelines: Diagnosis of
Tuberculosis in Adults and Children. Clin Infect Dis. 2017 Jan
15;64(2):e1-e33. [PubMed]
 74.
 Massud A, Syed Sulaiman SA, Ahmad N, Shafqat M, Chiau
Ming L, Khan AH. Frequency and Management of Adverse
Drug Reactions Among Drug-Resistant Tuberculosis Patients:
 Analysis From a Prospective Study. Front
Pharmacol. 2022;13:883483. [PMC free article] [PubMed]
 75.
 Treatment of Tuberculosis: Guidelines. 4th ed. World Health
Organization; Geneva: 2010. [PubMed]
 76.
 Singh KP, Carvalho ACC, Centis R, D Ambrosio L, Migliori
GB, Mpagama SG, Nguyen BC, Aarnoutse RE, Aleksa A, van
Altena R, Bhavani PK, Bolhuis MS, Borisov S, van T
Boveneind-Vrubleuskaya N, Bruchfeld J, Caminero JA,
Carvalho I, Cho JG, Davies Forsman L, Dedicoat M, Dheda
K, Dooley K, Furin J, García-García JM, Garcia-Prats A,
Hesseling AC, Heysell SK, Hu Y, Kim HY, Manga S, Marais
BJ, Margineanu I, Märtson AG, Munoz Torrico M,
Nataprawira HM, Nunes E, Ong CWM, Otto-Knapp R,
Palmero DJ, Peloquin CA, Rendon A, Rossato Silva D,
Ruslami R, Saktiawati AMI, Santoso P, Schaaf HS, Seaworth
B, Simonsson USH, Singla R, Skrahina A, Solovic I,
Srivastava S, Stocker SL, Sturkenboom MGG, Svensson EM,
Tadolini M, Thomas TA, Tiberi S, Trubiano J, Udwadia ZF,
Verhage AR, Vu DH, Akkerman OW, Alffenaar JWC,
Denholm JT. Clinical standards for the management of
adverse effects during treatment for TB. Int J Tuberc Lung
Dis. 2023 Jul 01;27(7):506-519. [PMC free article] [PubMed]
 77.
 Nanyonga SM, Kitutu FE, Kalyango J, Frank M, Kiguba R.
High Burden of Adverse Drug Reactions to Isoniazid
Preventive Therapy in People Living With HIV at 3 Tertiary
Hospitals in Uganda: Associated Factors. J Acquir Immune
Defic Syndr. 2022 Feb 01;89(2):215-221. [PubMed]
 78.
 Lazarus G, Tjoa K, Iskandar AWB, Louisa M, Sagwa EL,
Padayatchi N, Soetikno V. The effect of human
immunodeficiency virus infection on adverse events during
treatment of drug-resistant tuberculosis: A systematic review
and meta-analysis. PLoS One. 2021;16(3):e0248017. [PMC
free article] [PubMed]
 79.
 McIlleron H, Meintjes G, Burman WJ, Maartens G.
Complications of antiretroviral therapy in patients with
tuberculosis: drug interactions, toxicity, and immune
reconstitution inflammatory syndrome. J Infect Dis. 2007 Aug
15;196 Suppl 1:S63-75. [PubMed]
 80.
 Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N,
Tigay Z, Solodovnikova V, Liverko I, Moodliar R, Dodd M,
Ngubane N, Rassool M, McHugh TD, Spigelman M, Moore
DAJ, Ritmeijer K, du Cros P, Fielding K., TB-PRACTECAL
 Study Collaborators. A 24-Week, All-Oral Regimen for
Rifampin-Resistant Tuberculosis. N Engl J Med. 2022 Dec
22;387(25):2331-2343. [PubMed]
 81.
 Chakaya J, Khan M, Ntoumi F, Aklillu E, Fatima R, Mwaba
P, Kapata N, Mfinanga S, Hasnain SE, Katoto PDMC,
Bulabula ANH, Sam-Agudu NA, Nachega JB, Tiberi S,
McHugh TD, Abubakar I, Zumla A. Global Tuberculosis
Report 2020 - Reflections on the Global TB burden, treatment
and prevention efforts. Int J Infect Dis. 2021 Dec;113 Suppl
1(Suppl 1):S7-S12. [PMC free article] [PubMed]
 82.
 Bagcchi S. WHO's Global Tuberculosis Report 2022. Lancet
Microbe. 2023 Jan;4(1):e20. [PubMed]

14. Appendices
Glossary of terms related to TB.
Data tables for TB trends.
Graphs and charts comparing TB incidence and treatment outcomes.

This expanded content covers all the topics in detail and is designed to be
comprehensive enough for a full-length project on Tuberculosis. Let me
know if you need any further details or additions! 😊